NJ-WIPRO
12.6.2020 15:44:11 CEST | Business Wire | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that Wipro VirtuaDesk™, Wipro’s Desktop as a Service solution and Wipro's Digital Workspace solution, will join forces with Citrix Systems, Inc. (Nasdaq: CTXS) and Microsoft to help customers drive business continuity while executing operations within the boundaries of social distancing and other limitations that have currently become the new normal.
Wipro will integrate a host of services offered by Citrix and Microsoft to create high-performance virtual compute environments that leverage the power of cloud architecture and next-generation digital workspace technology. The combined solution will allow for rapid and easy deployment of secure and reliable digital workspaces (including application suites). This will let clients accommodate increased calls for remote work, which in many cases is a mandate. Clients will benefit while still adhering to cost, compatibility, resilience and performance objectives.
Citrix provides a complete range of digital workspace solutions designed to ensure that business operations can continue, whatever the disruption. Wipro will leverage many of these solutions, including Citrix® Workspaces Citrix® Virtual Apps and Desktops , Citrix Gateway and Citrix Analytics to help customers enable remote work and drive seamless productivity, while giving employees the flexibility to work from anywhere in a safe, secure and reliable manner.
Microsoft brings a comprehensive set of technologies to enable rapid implementation of cloud Virtual Desktop Infrastructure (VDI) solutions. Wipro will integrate Azure Active Directory, multi factor authentication, Windows Defender Advanced Threat Protection (ATP) for securing the desktop from external threats, FS Logix profiles for user profile management and Office 365 integration to non-persistent desktops. Windows 10 multi-session desktop delivery model will deliver the Windows 10 experience at an optimal value by eliminating the cost of certifying applications on a different operating system. In addition, Azure Analytics will provide real time performance analytics to improve user experience.
Wipro’s IP-based solution accelerators for cloud readiness assessment, cloud migration, application life cycle management and their user cloud migration tools will help organizations identify the right set of users and applications for cloud migration, saving time in Business Continuity Plan scenarios.
Satish Y, Vice President, Cloud & Infrastructure services, Wipro Limited, said, “The collaboration is a testament of our strength and our joint resolve to enhance the value we can create for our customers. We intend to bring together our strong complementary capabilities on virtualization tools & platforms, desktop & application integration and managed services, to help mitigate the impact of the pandemic. Wipro is a leader in workplace management services, Citrix in digital workspace solutions enabling remote work, and Microsoft brings expertise in cloud development. Together, we can equip enterprises to enhance employee experiences and connectivity to help achieve strategic business outcomes.”
“Natural disasters and public health emergencies can strike anywhere, at any time. And when they do, companies need to be prepared to protect their employees, their customers and the communities in which they operate,” Bronwyn Hastings - SVP, Worldwide Channel Sales & Ecosystems, Citrix . “This is where technology that enables remote work can be of real value. When a hurricane, wildfire, or pandemic prevents employees from physically getting to the office, they can connect to digital workspaces and access all of the tools and information they need to collaborate and get the work done from the safety of their homes without missing a step. We are pleased to align with our partners Wipro and Microsoft to deliver this.”
“Employees operating remotely has become the new norm. Windows Virtual Desktop provides companies with simplified management and a multi-session Windows 10 experience, without the constraints of the physical hardware or a person's location. Integration of Microsoft Azure Active Directory allows employees to work in a secure manner wherever they are. Wipro’s integration of these services along with Citrix will provide a secure and managed solution to enable remote workers.” said Giovanni Mezgec, General Manager at Microsoft .
In the new normal of remote work, companies must facilitate anytime, anywhere access to systems and information, to employees across business units and geographies. Technology is a key enabler of this, but it must be combined with more subtle elements, such as personalized and configurable services and service level agreements depending on enterprise location, language and the global talent spread. The new solution aims to deliver re-imagined solutions with a ‘glocal’ focus that ensures the right combination of global compute and storage capabilities with local presence, to create best-in-class virtual desktop experiences on cloud and on premises.
About VirtuaDesk™
Wipro’s VirtuaDesk ™, is an appliance-based desktop as a service solution focused creating and enhancing virtual workplaces. VirtuaDesk™ takes advantage of cloud architecture principles and the latest generation of hardware components to create cost effective and high-performance virtual desktops and applications. The solution also integrates with corporate IT infrastructure and supports existing workflows and processes. VirtuaDesk™ empowers users with a self-service portal that brings speed and agility to application access and real-time desktop management along with a reduction in storage costs and improvement in hardware utilization.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 175,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.
Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200612005348/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom